Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Ocul Immunol Inflamm ; 13(4): 317-25, 2005.
Article in English | MEDLINE | ID: mdl-16159724

ABSTRACT

AIM: To report a 47-year-old Japanese woman with a one-year history of Behçet's disease who complained of sudden bilateral visual loss with concurrent anterior ischemic optic neuropathy (AION). CASE REPORT: The patient's Snellen visual acuity was 0.1 (OD) and 0.3 (OS) of onset. There was bilateral mild anterior chamber inflammation. Bilateral optic disc pale swelling was observed without retinal exudates and edema. Fluorescein angiography demonstrated bilateral hypofluorescence of the optic disc in early frames but with no distinct retinal vasculitis. Visual field showed bilateral relative central scotoma and right altitudinal hemianopsia. Laboratory examination revealed an ESR of 26 mm in the first hour with a C-reactive protein level of < 0.3 mg/dl. Periocular injection of triamcinolone acetonide in both eyes without systemic corticosteroid administration improved her visual acuity to 0.7 (OD) and 1.2 (OS) within 45 days of onset. Bilateral optic disc swelling gradually resolved. In the early stages, fluorescein angiography demonstrated normal optic disc filling in both eyes. There was a residual right central scotoma on visual field. CONCLUSION: We observed an extremely rare case of simultaneous bilateral AION with Behçet's disease with marked visual recovery within 45 days of onset.


Subject(s)
Behcet Syndrome/complications , Optic Neuropathy, Ischemic/complications , Behcet Syndrome/diagnosis , Behcet Syndrome/drug therapy , Female , Fluorescein Angiography , Functional Laterality , Glucocorticoids/therapeutic use , Humans , Injections , Middle Aged , Optic Disk/pathology , Optic Neuropathy, Ischemic/diagnosis , Optic Neuropathy, Ischemic/drug therapy , Scotoma/complications , Scotoma/diagnosis , Scotoma/drug therapy , Triamcinolone Acetonide/therapeutic use , Visual Acuity , Visual Fields
2.
Ocul Immunol Inflamm ; 13(4): 301-4, 2005.
Article in English | MEDLINE | ID: mdl-16159721

ABSTRACT

PURPOSE: To compare the conjunctival flora of human immunodeficiency virus (HIV)-positive and HIV-negative patients. Also, to assess the prophylactic effect of oral clarithromycin against Mycobacterium avium complex on the conjunctival flora of HIV-positive patients. METHODS: Ninety-four eyes of 47 HIV-positive patients and 122 eyes of 61 control patients were examined. All participants had a detailed anterior segment examination, including conjunctival cultures and laboratory blood tests. Culture results for different organisms were evaluated by chi-square analysis between the groups. The effect of systemic antibiotic treatment on the conjunctival flora of patients with HIV infection was evaluated by chi-square analysis. RESULTS: Bacterial organisms in the conjunctival sac were detected in four out of 28 (14.3%) eyes of HIV-positive patients treated with systemic clarithromycin and in 32 out of 66 (48.5%) eyes of HIV-positive patients without systemic clarithromycin treatment (p < 0.01). The CD4-positive T-cell counts in these groups were 158/microl and 416/microl, respectively (p < 0.01). Bacterial organisms were also detected in 46 of 122 (37.7%) control eyes. No difference was observed in the types and proportions of organisms isolated from the conjunctiva between HIV-positive patients without systemic clarithromycin treatment and controls. CONCLUSION: There was no difference between the conjunctival flora of HIV-negative and HIV-positive patients. Systemic clarithromycin treatment decreased the conjunctival flora of HIV patients, including those who had a CD4 count that was less than 50/microl.


Subject(s)
Conjunctiva/microbiology , HIV Infections/microbiology , Adult , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis , Bacteriological Techniques , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/immunology , Clarithromycin/therapeutic use , Colony Count, Microbial , Conjunctiva/drug effects , Drug Combinations , Female , HIV Infections/drug therapy , HIV Infections/immunology , Humans , Male , Sulfamethoxazole/analogs & derivatives , Sulfamethoxazole/therapeutic use , Trimethoprim/therapeutic use
3.
J Immunol ; 174(1): 491-7, 2005 Jan 01.
Article in English | MEDLINE | ID: mdl-15611275

ABSTRACT

Choroidal neovascularization (CNV), or choroidal angiogenesis, is the hallmark of age-related macular degeneration and a leading cause of visual loss after age 55. The pathogenesis of new choroidal vessel formation is poorly understood. Although inflammation has been implicated in the development of CNV, the role of complement in CNV has not been explored experimentally. A reliable way to produce CNV in animals is to rupture Bruch's membrane with laser photocoagulation. A murine model of laser-induced CNV in C57BL/6 mice revealed the deposition of C3 and membrane attack complex (MAC) in the neovascular complex. CNV was inhibited by complement depletion using cobra venom factor and did not develop in C3(-/-) mice. Anti-murine C6 Abs in C57BL/6 mice inhibited MAC formation and also resulted in the inhibition of CNV. Vascular endothelial growth factor, TGF-beta2, and beta-fibroblast growth factor were elevated in C57BL/6 mice after laser-induced CNV; complement depletion resulted in a marked reduction in the level of these angiogenic factors. Thus, activation of complement, specifically the formation of MAC, is essential for the development of laser- induced choroidal angiogenesis in mice. It is possible that a similar mechanism may be involved in the pathophysiology of other angiogenesis essential diseases.


Subject(s)
Choroid/blood supply , Choroidal Neovascularization/physiopathology , Complement C3/metabolism , Complement Membrane Attack Complex/metabolism , Animals , Choroidal Neovascularization/etiology , Choroidal Neovascularization/metabolism , Complement Activation/physiology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Fibroblast Growth Factors/metabolism , Immunohistochemistry , Lasers/adverse effects , Male , Mice , Microscopy, Confocal , Reverse Transcriptase Polymerase Chain Reaction , Transforming Growth Factor beta/metabolism , Transforming Growth Factor beta2 , Vascular Endothelial Growth Factor A/metabolism
4.
J Immunol ; 172(11): 7086-94, 2004 Jun 01.
Article in English | MEDLINE | ID: mdl-15153531

ABSTRACT

This study was undertaken to identify and characterize the Ag responsible for the induction of experimental autoimmune anterior uveitis (EAAU). Melanin-associated Ag isolated from bovine iris and ciliary body was digested with the proteolytic enzyme V8 protease to solubilize the proteins and the pathogenic protein was purified to homogeneity. Lewis rats were sensitized to various fractions and investigated for the development of anterior uveitis and an immune response to the purified Ag. The uveitogenic Ag had a mass of 22 kDa (SDS-PAGE) and an isoelectric point of 6.75. The N-terminal amino acid sequence of this protein demonstrated 100% homology with the bovine type I collagen alpha-2 chain starting from amino acid 385 and will be referred to as CI-alpha2 (22 kDa). Animals immunized with bovine CI-alpha2 (22 kDa) developed both cellular and humoral immunity to the Ag. They developed anterior uveitis only if the CI-alpha2 chain underwent proteolysis and if the bound carbohydrates were intact. EAAU induced by CI-alpha2 (22 kDa) can be adoptively transferred to naive syngenic rats by primed CD4(+) T cells. EAAU could not be induced by the adoptive transfer of sera obtained from animals immunized with CI-alpha2 (22 kDa). The alpha-1 and alpha-2 chains (intact or proteolytically cleaved) of type I collagen from calfskin were not pathogenic. Although human anterior uveitis has been historically characterized as a collagen disease, this is first time collagen has been directly identified as the target autoantigen in uveitis.


Subject(s)
Autoantigens/immunology , Autoimmune Diseases/etiology , Collagen Type I/immunology , Uveitis, Anterior/etiology , Adoptive Transfer , Amino Acid Sequence , Animals , Autoantigens/isolation & purification , Autoimmune Diseases/immunology , Immune Sera/immunology , Male , Molecular Sequence Data , Organ Specificity , Protein Processing, Post-Translational , Rats , Rats, Inbred Lew , Uveitis, Anterior/immunology
5.
Proc Natl Acad Sci U S A ; 100(5): 2679-84, 2003 Mar 04.
Article in English | MEDLINE | ID: mdl-12589025

ABSTRACT

Age-related macular degeneration (AMD) is the leading cause of blindness after age 55 in the industrialized world. Severe loss of central vision frequently occurs with the exudative (wet) form of AMD, as a result of the formation of a pathological choroidal neovasculature (CNV) that damages the macular region of the retina. We tested the effect of an immunotherapy procedure, which had been shown to destroy the pathological neovasculature in solid tumors, on the formation of laser-induced CNV in a mouse model simulating exudative AMD in humans. The procedure involves administering an Icon molecule that binds with high affinity and specificity to tissue factor (TF), resulting in the activation of a potent cytolytic immune response against cells expressing TF. The Icon binds selectively to TF on the vascular endothelium of a CNV in the mouse and pig models and also on the CNV of patients with exudative AMD. Here we show that the Icon dramatically reduces the frequency of CNV formation in the mouse model. After laser treatment to induce CNV formation, the mice were injected either with an adenoviral vector encoding the Icon, resulting in synthesis of the Icon by vector-infected mouse cells, or with the Icon protein. The route of injection was i.v. or intraocular. The efficacy of the Icon in preventing formation of laser-induced CNV depends on binding selectively to the CNV. Because the Icon binds selectively to the CNV in exudative AMD as well as to laser-induced CNV, the Icon might also be efficacious for treating patients with exudative AMD.


Subject(s)
Choroid/blood supply , Choroid/drug effects , Immunotherapy/methods , Macular Degeneration/therapy , Neovascularization, Pathologic , Adenoviridae/genetics , Animals , Cells, Cultured , DNA, Complementary/metabolism , Disease Models, Animal , Gene Library , Genetic Vectors , Humans , Lasers , Liver/metabolism , Mice , Mice, Inbred C57BL , Microscopy, Confocal , Protein Binding , Retina/drug effects , Swine , Thromboplastin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...